Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
Cash Position As of September 30, 2024, cash, cash equivalents and marketable securities totaled approximately $85 million, with a subsequent public offering raising approximately $80.8 million in net proceeds, leading to a pro forma cash position of approximately $166 million.
Revenue Revenues for Q3 2024 were approximately $2.3 million, a decrease from approximately $6.2 million in Q3 2023, attributed to the ratable recognition of the $40 million received from the U.S. exclusive commercialization and distribution agreement with Nippon Shinyaku.
Research and Development Expense R&D expenses for Q3 2024 were approximately $11 million, compared to approximately $9.5 million in Q3 2023, indicating an increase in investment in R&D activities.
General and Administrative Expense G&A expenses for Q3 2024 were approximately $2.2 million, up from approximately $1.8 million in Q3 2023, reflecting increased operational costs.
Net Loss Net loss for Q3 2024 was approximately $12.6 million, compared to a net loss of approximately $6.4 million for Q3 2023, indicating a higher loss year-over-year due to increased expenses.
Net Loss for 9 Months Net loss for the 9 months ended September 30, 2024, was approximately $33.4 million, compared to a net loss of approximately $21.5 million for the same period in 2023, reflecting a significant increase in losses year-over-year.
BLA Submission: Capricor plans to file a Biologics License Application (BLA) for full approval of deramiocel for treating cardiomyopathy associated with DMD, based on existing cardiac data from Phase II studies.
New Indication Exploration: Capricor is exploring the potential to expand deramiocel's indication to Becker muscular dystrophy, as the cardiac manifestations are similar to DMD.
Exosome Program Development: Capricor is advancing its StealthX exosome platform technology for drug delivery and vaccine development, with plans for an IND submission.
Market Expansion: Capricor has entered into a term sheet with Nippon Shinyaku for marketing, sales, and distribution of deramiocel in Europe, with potential milestone payments totaling $1.5 billion.
Commercialization Strategy: Capricor is preparing for the launch of deramiocel in collaboration with Nippon Shinyaku, leveraging their existing market presence in DMD.
Manufacturing Capacity Expansion: Capricor is scaling up manufacturing capabilities with a new facility in San Diego to meet anticipated demand for deramiocel.
Public Offering: In October, Capricor completed a public offering raising approximately $86 million, enhancing its cash position to approximately $165 million.
Regulatory Strategy: Capricor is working closely with the FDA to ensure a smooth BLA submission process and anticipates a priority review due to its RMAT designation.
Collaboration with Nippon Shinyaku: Capricor is actively collaborating with Nippon Shinyaku to prepare for the launch of deramiocel, utilizing their established infrastructure in the DMD market.
Regulatory Risks: The company is preparing for potential FDA approval of deramiocel, which involves uncertainties related to regulatory filings and the review process. Although they expect a priority review due to their RMAT designation, there is no guarantee of approval.
Manufacturing Challenges: Capricor is scaling up manufacturing capabilities to meet anticipated demand for deramiocel. The reliance on transplant-qualified human hearts for production poses risks related to supply chain and sourcing.
Market Competition: The company faces competitive pressures from existing and future therapies for DMD, particularly as they seek to establish deramiocel as a first-in-class treatment for cardiomyopathy.
Financial Risks: Despite raising approximately $86 million, the company reported a net loss of approximately $12.6 million for Q3 2024, indicating ongoing financial challenges as they invest in R&D and manufacturing.
Economic Factors: The potential for reimbursement from payers is uncertain, and the company must navigate market access challenges, especially in light of the competitive landscape for DMD therapies.
Global Market Expansion: Capricor plans to market deramiocel in regions outside the U.S. and Japan, which introduces risks related to regulatory approvals and market penetration in those areas.
BLA Submission: Capricor plans to file a Biologics License Application (BLA) for full approval of deramiocel for treating cardiomyopathy associated with DMD, with the first module submitted and full submission expected by year-end 2024.
Market Opportunity: Approximately 50% to 60% of the overall DMD population in the U.S. (around 8,000 people) would be eligible for treatment with deramiocel.
Manufacturing Expansion: Capricor is in late-stage planning for scaling up manufacturing capabilities to meet anticipated demand, with a goal to have another facility online within a year of launch.
Collaboration with Nippon Shinyaku: Capricor has entered into a term sheet with Nippon Shinyaku for marketing, sales, and distribution of deramiocel in Europe, with potential milestone payments totaling $1.5 billion.
Exploration of Becker Muscular Dystrophy: Capricor is exploring the opportunity to expand deramiocel's indication to Becker muscular dystrophy, with plans to make this an important goal for 2025.
FDA Review Timeline: Capricor expects to hear from the FDA by the end of Q1 2025 regarding the status of the BLA application, with a potential PDUFA date set for the second half of 2025.
Financial Position: Post-public offering, Capricor has approximately $165 million in cash, providing a strong runway into 2027 to support manufacturing expansion and commercial operations.
Revenue Expectations: Capricor anticipates rapid adoption of deramiocel upon approval, with initial market entry involving approximately 100 patients transitioning from open-label extension groups.
Clinical Trial Plans: Capricor is planning for an IND for a therapeutic exosome program and is collaborating with NIAID for a Phase I clinical trial of their StealthX vaccine candidate.
Public Offering: Completed an oversubscribed public offering of common stock, raising approximately $86 million.
Cash Position: Post-offering, cash, cash equivalents, and marketable securities total approximately $165 million.
Milestone Payments: Potential milestone payments totaling $1.5 billion from Nippon Shinyaku for marketing, sales, and distribution in Europe.
Revenue Share: In the U.S., Capricor is entitled to between 30% to 50% of revenue share based on sales of deramiocel.
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
The earnings call highlights significant progress in product development, strategic partnerships, and financial performance. Positive interim results in the Phase III trial, increased revenue, and reduced net loss are notable. The Q&A reveals confidence in regulatory strategies and strong safety profiles, despite some uncertainties. The potential for milestone payments and global expansion, along with a strong cash position, supports a positive outlook. However, increased R&D expenses and lack of specific guidance on milestone triggers and partnerships temper enthusiasm slightly. Overall, the stock is likely to see a positive movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
